GENESIS LED WANDS
Device Facts
| Record ID | K131142 |
|---|---|
| Device Name | GENESIS LED WANDS |
| Applicant | Genesis Biosystems, Inc. |
| Product Code | GEX · General, Plastic Surgery |
| Decision Date | Nov 27, 2013 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.4810 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
Red 627nm: Generally indicated for use in dermatology for treatment of superficial, benign vascular and pigmented lesions. Blue 415nm: Generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris.
Device Story
Genesis LED Wands utilize high-end Light Emitting Diodes (LEDs) for photobiostimulation. The device emits specific wavelengths: 627 nm (Red) and 415 nm (Blue), both at 135mW/cm² with a 50% pulsed duty cycle. The system consists of a base unit containing power supplies and a control unit, with LED wands as the delivery mechanism. The device is non-invasive and does not contact the skin. It is intended for use in a clinical setting by healthcare professionals. By applying specific light wavelengths to tissue, the device aims to treat dermatological conditions, including superficial vascular/pigmented lesions and moderate inflammatory acne vulgaris, providing a therapeutic benefit to the patient.
Clinical Evidence
No clinical trials were performed. Safety and effectiveness are supported by bench testing, including electrical safety and EMC compliance (IEC 60601-1, IEC 60601-1-2), laser classification (IEC 60825-1), and risk management (ISO 14971:2009).
Technological Characteristics
LED-based photobiostimulation device. Wavelengths: 627 nm (Red), 415 nm (Blue). Output: 135mW/cm², 50% pulsed duty cycle. Components: Base unit (power/control), LED wand applicators. Standards: IEC 60601-1 (electrical safety), IEC 60601-1-2 (EMC), IEC 60825-1 (laser classification), ISO 14971 (risk management). Non-contact application.
Indications for Use
Indicated for patients requiring dermatological treatment for superficial, benign vascular and pigmented lesions (Red 627nm) or moderate inflammatory acne vulgaris (Blue 415nm).
Regulatory Classification
Identification
(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
Predicate Devices
Submission Summary (Full Text)
{0}------------------------------------------------
Page 1 of 3
#### 2 7 2013 NOV
### 510(K) Summary
This summary of 510(k) information is being submitted in accordance with the requirements of 21 CFR 1040.10 & 1040.11
| 1. General Information | |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Submitter: | Genesis Biosystems, Inc.<br>1500 Eagle Court<br>Lewisville, TX 75057<br>972-315-7888 (direct)<br>972-315-7818 (fax) |
| Contact Person: | Jim Lafferty<br>President<br>Genesis Biosystems, Inc.<br>1500 Eagle Court Lewisville, TX 75057<br>jgroves@genesisbiosystems.com |
| Manufacturing Facility: | Genesis Biosystems, Inc.<br>1500 Eagle Court<br>Lewisville, TX 75057 |
| Summary Preparation Date: | 15-April-2013 |
| 2. Names | |
| Device Name: | Genesis LED Device |
| Common Name: | Laser instrument, surgical, powered |
| Regulation: | 878.4810 |
| Product Code: | GEX |
#### 3. Predicate Devices
Revitalight Skincare System (K042630) Lightwave Deluxe (K082586)
#### 4. Device Description
The Genesis LED Device uses high-end Light Emitting Diodes (LED's) to distribute the specific wavelengths of light it uses. This technology is commonly referred to as Photobiostimulation, Light Emitting Diode Therapy (LEDT), or LED's. The application of LED's to tissue is non-invasive. The Genesis LED Wands emit light at the following wavelengths:
| Device: | Wavelength: | Output: |
|-----------------------|-------------|----------------------------------|
| Genesis LED Wand RED | 627 nm | 135mW/cm², pulsed 50% duty cycle |
| Genesis LED Wand BLUE | 415 nm | 135mW/cm², pulsed 50% duty cycle |
#### 5. Indications for Use
| LED Color | Wavelength | Indication: |
|-----------|------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Red | 627nm | Generally indicated for use in dermatology for the treatment of superficial,<br>benign vascular and pigmented legions |
| Blue | 415nm | Generally indicated to treat dermatological conditions and specifically<br>indicated to treat moderate inflammatory acne vulgaris |
{1}------------------------------------------------
#### 6. Performance Data
Based upon an analysis of the overall performance characteristics for the device, Genesis Biosystems, Inc. believes that no significant differences exist between the Genesis LED Wands and the predicate devices referenced in this document.
#### 7. Comparison to Predicate Devices
| Decision Process | Decision | K042630 | K082586 |
|----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Does new device have same<br>Indication Statement (as marketed<br>device? | Yes. The Genesis LED<br>Wand device has the<br>same intended use as<br>predicate devices noted. | The RevitaLight<br>Skin Care System<br>generally<br>indicated to treat<br>dermatological<br>conditions and<br>specifically<br>indicated to treat<br>moderate<br>inflammatory<br>acne vulgaris (Blue<br>Pulsars) | The LightWave Deluxe Red light is indicated<br>for use in dermatology for treatment of<br>superficial, benign vascular, and pigmented<br>legions. (Red Pulsars) |
| Does new device have same<br>technological characteristics, e.g.,<br>design, materials, etc? | Yes. The Genesis LED<br>Wand device has the<br>same technological<br>characteristics utilizing<br>light emitting diodes, a<br>power source and means<br>of controlling both. | Base unit contains<br>power supplies<br>and control unit.<br>Pulsator<br>attachments<br>contain the light<br>emitting diodes<br>and connect to<br>the base unit. | The base unit contains the power supplies and<br>the control unit. The LED panel is attached to<br>the end of the arms and then positioned for<br>patient treatment. |
| Are the descriptive characteristics<br>precise enough to ensure<br>equivalence ? | Yes. The devices are<br>sufficiently characterized<br>to ensure equivalence. | Operates as blue<br>(420nm), yellow<br>(590nm), and red<br>(625nm) LED<br>source at<br>80mW/cm². LED<br>array panel hand<br>held device. | Operates as red (630nm to 830nm) LED<br>source at 4.73J/cm². |
| Performance data demonstrate<br>equivalence? | Yes. The device<br>performance<br>demonstrates<br>equivalence. | Operates<br>equivalently as<br>yellow (590nm)<br>and red (625 nm)<br>LED source. | Operates equivalently as a red (630nm-<br>645nm) LED source. |
{2}------------------------------------------------
#### 8. Testing
Performance data in the form of clinical trials were not necessary as the device uses the same technology and intended use as the predicate devices.
Testing information demonstrating safety and effectiveness of the Genesis LED wands in the intended environment of use are supported by testing that was conducted in accordance with the following standard(s): ISO 14971: 2009
Biocompatibility testing was not performed as the Genesis LED Wands do not make contact with the skin at any time before or during treatments.
Testing to demonstrate compliance to the recognized electrical safety and EMC requirements of IEC 60601-1 and IEC 60601-1-2 have been performed by an independent, accredited laboratory.
Testing to determine laser classification according to IEC 60825-1 was performed by an independent, accredited laboratory.
#### 9. Conclusion
Based upon an analysis of the overall characteristics for the device in comparison to the predicates, Genesis Biosystems, Inc. concludes that the Genesis LED Wands are substantially equi
{3}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-00002
Genesis Biosystems, Incorporated Mr. Jim Lafferty President 1500 Eagle Court Lewisville, Texas 75057
November 27, 2013
Re: K131142
Trade/Device Name: Genesis LED Wands Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: October 16, 2013 Received: October 17, 2013
Dear Mr. Lafferty:
We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Ilsting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA 's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
{4}------------------------------------------------
Page 2 - Mr. Jim Lafferty
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
# Joshua C. Nipper -S
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Acting Director Division of Surgical Devices Office of Device Evaluation
For
Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
# Indications for Use
510(k) Number (if known): K131142
Device Name: Genesis LED Wands
Indications For Use:
| Led Color | Wavelength | Indication: |
|-----------|------------|---------------------------------------------------------------------------------------------------------------------------------|
| Red | 627nm | Generally indicated for use in dermatology for treatment of superficial, benign vascular and pigmented lesions |
| Blue | 415nm | Generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris. |
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
## (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of Center for Devices and Radiological Health (CDRH)
Joshua C. - C
Page 1 of ____________________________________________________________________________________________________________________________________________________________________
